Us2.ca vs Imbio PHA (4.0.0)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Eko.Ai Pte Ltd. D/B/A Us2.Ai
VS
by Imbio (a subsidiary of 4DMedical)

AI Verdict

Us2.ai specializes in fully automated echocardiography analysis, providing comprehensive cardiac reports and disease detection across various conditions. In contrast, Imbio PHA (4.0.0) focuses on analyzing CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation and aid in diagnosing pulmonary embolism and hypertension. While both are AI-powered tools for cardiac imaging, their distinct input modalities (echocardiography vs. CTPA) make them suitable for different diagnostic pathways.

Choose Us2.ca if…

Choose Us2.ai if your primary need is a fully automated, zero-click solution for comprehensive echocardiography analysis and reporting. This tool is ideal for cardiology departments seeking to enhance diagnostic accuracy and workflow efficiency by generating structured cardiac reports in seconds, covering a wide range of cardiac structural and functional parameters and AI-powered disease detection.

View Us2.ca →

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA if your focus is on rapidly assessing right ventricular dilation and risk stratifying patients from CT pulmonary angiogram (CTPA) scans. This tool is specifically designed for pulmonology and radiology departments needing automated measurements of cardiac structures like RV/LV and and PA/Ao ratios to aid in the diagnosis and management of pulmonary embolism and hypertension.

View Imbio PHA (4.0.0) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Us2.ca Imbio PHA (4.0.0)
Pricing Contact for pricing Unknown
Deployment Cloud, On-premise Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Unknown

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Us2.ca Imbio PHA (4.0.0)
Product Name Us2.ca Imbio PHA (4.0.0)
Company Eko.Ai Pte Ltd. D/B/A Us2.Ai Imbio
Description FDA-cleared and CE-marked AI platform that fully automates echocardiography analysis, delivering comprehensive, structured cardiac reports in seconds to enhance diagnostic accuracy and workflow efficiency. FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
Primary Imaging Modality Echocardiography CT pulmonary angiogram (CTPA)
Key Features (Examples) Fully automated echocardiography analysis (zero clicks), Real-time processing and structured report generation, AI-powered disease detection (e.g., Cardiac Amyloidosis, Heart Failure, Aortic Stenosis, Pulmonary Hypertension) Automated measurement of right and left ventricle diameters, Automated measurement of main pulmonary artery and aorta diameters, Calculates RV/LV and PA/Ao ratios
Specialties Cardiology, Radiology Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Us2.ca and Imbio PHA (4.0.0).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Us2.ai is designed for fully automated echocardiography analysis, processing 2D, Doppler, M-mode, and strain imaging. Imbio PHA (4.0.0) analyzes CT pulmonary angiogram (CTPA) scans to measure cardiac structures.
Us2.ai enhances diagnostic accuracy and workflow efficiency by delivering comprehensive cardiac reports and AI-powered disease detection for conditions like Cardiac Amyloidosis, Heart Failure, Aortic Stenosis, and Pulmonary Hypertension. Imbio PHA (4.0.0) aids in the diagnosis and risk stratification of pulmonary embolism and hypertension by assessing potential right ventricular dilation from CTPA scans.
Us2.ai generates comprehensive, structured cardiac reports with guideline-based measurements and disease indication conclusions, including various structural and functional parameters. Imbio PHA (4.0.0) automatically measures right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios, providing annotated DICOM images and PDF summary reports.
Us2.ai integrates with ultrasound devices, PACS, CVIS, and EMR systems, aiming for zero-click analysis and real-time processing. Imbio PHA (4.0.0) integrates with native DICOM tools and workflows, automatically delivering analysis outputs like 3D DICOM series and quantitative reports directly into the patient study in PACS.
AI Tool Finder
AI-powered search. Results may not be comprehensive.